X4 Pharmaceuticals, Inc. Gains 52.59%
X4 Pharmaceuticals, Inc. (XFOR:NASDAQ) soared at $0.74, a gain of 52.6%. On Wed, Jan 29, 2025, XFOR:NASDAQ hit a New 2-Week High of $0.74. The stock got featured on our News Catalysts scanner on Fri, Jan 24, 2025 at 09:39 AM in the 'BIOTECH' category. From Wed, Jan 15, 2025, the stock recorded 44.44% Up Days and 40.00% Green Days
The stock spiked on Tue, Dec 31, 2024 at $0.89 with a volume of 1M+.
About X4 Pharmaceuticals, Inc. (XFOR:NASDAQ)
Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.
Top 10 Gainers:
- Diginex Limited (DGNX:NASDAQ), 234.56%
- LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 192.31%
- Biomotion Sciences (SLXN:NASDAQ), 132.59%
- Signing Day Sports Inc. (SGN:NYSEMKT), 123.71%
- 36Kr Holdings Inc. (KRKR:NASDAQ), 122.17%
- Smart for Life Inc. (SMFL:NASDAQ), 87.5%
- Sacks Parente Golf Inc. (SPGC:NASDAQ), 55.26%
- Banzai International, Inc. Class A Common Stock (BNZI:NASDAQ), 54.4%
- X4 Pharmaceuticals, Inc. (XFOR:NASDAQ), 52.59%
- Ranpak Holdings Corp. (PACK:NYSE), 46.86%